Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine

Código QR

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine

Background: Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known. Methods: 77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chin-Shern Lau, Soon Kieng Phua, Ya-Li Liang, Helen May-Lin Oh, Tar-Choon Aw
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 mRNA vaccines spike antibodies neutralizing antibodies Medicine R
Acceso en línea:	https://doaj.org/article/832be0fd0d2b48ddb2de017eb810ccaf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
por: Ilaria Vicenti, et al.
Publicado: (2021)

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
por: Meredith E. Davis-Gardner, et al.
Publicado: (2020)

SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity
por: Michihito Sasaki, et al.
Publicado: (2021)

SARS‐CoV‐2 infection shortly after BNT162b2 vaccination results in high anti‐spike antibody levels in nursing home residents and staff
por: Doris Urlaub, et al.
Publicado: (2021)

Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential
por: Slawomir Kubik, et al.
Publicado: (2021)

Perspectives on Assembling Coronavirus Spikes on Fiber Optics to Reveal Broadly Recognizing Antibodies and Generate a Universal Coronavirus Detector
por: Marzhan Sypabekova, et al.
Publicado: (2021)

Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations
por: Damiano Buratto, et al.
Publicado: (2021)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Rana Shibli, et al.
Publicado: (2021)

Follow-up study on COVID-19 survivors one year after discharge from hospital
por: Yumiao Zhao, et al.
Publicado: (2021)

Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
por: Frank-Peter Tillmann, et al.
Publicado: (2021)

Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIV<sub>smm/mac</sub> Envelope Glycoprotein Uncouple Antibody-Dependent Cellular Cytotoxicity from Neutralization
por: Benjamin von Bredow, et al.
Publicado: (2019)

Humoral Immunity to Hantavirus Infection
por: Taylor B. Engdahl, et al.
Publicado: (2020)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
por: Krzysztof Lukaszuk, et al.
Publicado: (2021)

Structural Studies on the Shapeshifting Murine Norovirus
por: Michael B. Sherman, et al.
Publicado: (2021)

SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
por: Vimvara Vacharathit, et al.
Publicado: (2021)

IgG Study of Blood Sera of Patients with COVID-19
por: Elena Kazachinskaia, et al.
Publicado: (2021)

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
por: Hamad Ali, et al.
Publicado: (2021)

Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen
por: Anita Verma, et al.
Publicado: (2018)

Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects
por: Franck P. Dupuy, et al.
Publicado: (2019)

In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
por: Silvere Pagant, et al.
Publicado: (2021)

Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion
por: Lisa C. Lindesmith, et al.
Publicado: (2018)

Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques
por: Kim J. Hasenkrug, et al.
Publicado: (2021)

Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects
por: Constant Gillot, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Davide Ferrari, et al.
Publicado: (2021)

ROLE OF IL-6 IN EXPERIMENTAL ARTHRITIS CAUSED BY TRANSFER OF ARTHRITOGENIC ANTIBODIES
por: M. S. Drutskaya, et al.
Publicado: (2016)

Norovirus Escape from Broadly Neutralizing Antibodies Is Limited to Allostery-Like Mechanisms
por: Abimbola O. Kolawole, et al.
Publicado: (2017)

Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen
por: Ilona Rissanen, et al.
Publicado: (2021)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
por: Hao Zhou, et al.
Publicado: (2021)

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
por: Serge Goldman, et al.
Publicado: (2021)

Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection
por: M. Muenchhoff, et al.
Publicado: (2020)

Studies on Growth Characteristics and Cross-Neutralization of Wild-Type and Delta SARS-CoV-2 From Hisar (India)
por: Nitin Khandelwal, et al.
Publicado: (2021)

Tenacious Researchers Identify a Weakness in All Ebolaviruses
por: Rebecca M. DuBois
Publicado: (2018)

Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies
por: Emily N. Gallichotte, et al.
Publicado: (2019)

Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus
por: Haihai Jiang, et al.
Publicado: (2020)

Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
por: Gururaj Rao Deshpande, et al.
Publicado: (2021)

Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
por: Georg Beilhack, et al.
Publicado: (2021)

S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit
por: Phuong Nguyen-Contant, et al.
Publicado: (2020)

Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19
por: Tianchuan Zhu, et al.
Publicado: (2021)

Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
por: Julie Demaret, et al.
Publicado: (2021)

The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal Antibody
por: Daniela Luz, et al.
Publicado: (2021)